FDA Clears Implantable Device for Central Sleep Apnea — Physician’s First Watch

Medical News |
October 10, 2017

FDA Clears Implantable Device for Central Sleep Apnea

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

The FDA has cleared the Remedē System to treat patients with moderate-to-severe central sleep apnea.

With this system, a battery pack is implanted under the skin of the upper chest. Thin wires are inserted into the patient's phrenic nerve, which stimulates breathing. When the device senses that normal breathing has been interrupted during sleep, it stimulates the phrenic nerve to move the diaphragm and prompt normal breathing.

In a trial of nearly 150 patients with central sleep apnea, most of whom had heart failure, the system reduced the apnea hypopnea index score by 50% in more than 51% of patients at 6 months. In comparison, among those with the device implanted but not activated, only 11% had a score reduction of 50% or more.

Some of the common adverse events included concomitant device interaction, infection at the implant site, and swelling and local tissue damage or pocket erosion.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.